Brief: Hungary Richter CEO says risks in U.S. market currently moderate
May 13 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU CEO GABOR ORBAN SAYS: FULL-YEAR GUIDANCE OF AROUND 10% INCREASE IN BOTH REVENUES AND CLEAN EBIT IS MAINTAINED DEAL WITH GRANATA BIO ANNOUNCED TODAY SHOWS MOVE TOWARDS U.S. FERTILITY MARKET RISKS IN THE U.S. MARKET FROM TARIFFS AND PRICING CHANGES ARE MODERATE FOR OUR PRESENT AND NEAR FUTURE Further company coverage: GDRB.BU (Reporting by Anita Komuves) ((KOMUVES.Anita@thomsonreuters.com;))
Recent news on Gedeon Richter
See all newsBrief: Hungary's Richter says US FDA accepted for review its new drug application for Fylrevy
Brief: Hungary's Richter Upgrades 2026 Pharma Clean EBIT Guidance To Double-Digit Growth
development partnership in Tirzepatide
AI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection